Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a deal worth up to $50 million in biobucks. Organovo’s stock ...

“We are excited to deliver FXR314 and our FXR program to Lilly for Phase 2 and further development. Their world-class development excellence and dedication to delivering for patients will provide an ...

Organovo Holdings, Inc. announced that it will be acquired by Eli Lilly and Company, which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease ...

Organovo (ONVO) Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under this transaction, Organovo will receive an ...

Following the announcement, shares in Organovo were trading a hefty 270% higher by lunchtime Tuesday. The deal will see Lilly acquire Organovo’s FXR program, including its lead asset, FXR314. All the ...

If you’re stuck on today’s Wordle answer, we’re here to help—but beware of spoilers for Wordle 1340 ahead. Let's start with a few hints. There are three vowels out of the five letters in ...